RxDoctor Payments Data

David Evans, MD

Cardiovascular Disease · Searcy, ARNPI 1144255928

Payments from drug & device makers

$1,207in general payments, 2019–2025

Across 62 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$305
  • Medtronic$160
  • Abiomed$140
  • Amgen$106
  • Shockwave Medical, Inc$80
  • Baxter Healthcare$72
  • plus $345 from 12 others

What the payments were for

  • Food & beverage$1,207100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,207 in reported general payments places this provider in the 25th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$237,896
Medicare patients
1,328
Services billed
4,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban841$687,342
XareltoRivaroxaban229$184,961
EntrestoSacubitril/Valsartan117$114,119
BrilintaTicagrelor53$36,831
MultaqDronedarone Hcl23$29,529
Metoprolol Succinate1,239$18,641
CorlanorIvabradine Hcl24$17,875
JardianceEmpagliflozin23$16,482
FarxigaDapagliflozin Propanediol16$16,402
Repatha PushtronexEvolocumab21$14,056
Atorvastatin Calcium1,271$13,136
Repatha SureclickEvolocumab21$12,205
Isosorbide Mononitrate ErIsosorbide Mononitrate1,139$11,447
Losartan Potassium1,059$9,439
Potassium Chloride550$8,785

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$687,342841 claims
Johnson & JohnsonXarelto$17$184,961229 claims
NovartisEntresto$305$114,119117 claims
AstraZenecaBrilinta, Farxiga$38$53,23369 claims
AmgenCorlanor$106$17,87524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Searcy

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →